Nasdaq GlobeNewswire

Fraser Institute News Release: Ottawa’s drug-pricing changes risk limiting patient access to new medicines

VANCOUVER, British Columbia, July 20, 2018 (GLOBE NEWSWIRE) -- The federal government’s plan to lower the cost of patented pharmaceuticals in Canada through new regulations seriously risks limiting patient access to new innovative drugs, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.

CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology

"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies”

BioStem Technologies (BSEM) Subsidiary Nesvik Pharmaceuticals Announces the Completion of An Asset Purchase of Multiple New Drug Compounds and Launches Joint Development Venture with CCM Pharma Solutions

Pompano Beach, FL, July 19, 2018 (GLOBE NEWSWIRE) -- Nesvik Pharmaceuticals (f/k/a BioStem Pharmaceuticals), a subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, is pleased to announce the Asset Purchase of multiple New Drug Compounds from CCM Pharma Solutions establishing the beginning of a Joint Venture.

Groupe Santé Devonian annonce un financement privé, sans syndicat de courtiers, de débentures convertibles

NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS

Devonian Health Group announces Non-Brokered Financing by way of a private placement of Convertible Debenture

 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES.

Arbutus to Report Second Quarter 2018 Financial Results

WARMINSTER, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Thursday, August 2, 2018. The schedule for the press release and conference call/webcast are as follows:

Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results

 

SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal first-quarter 2019 operating and financial highlights.  In advance of the call on August 9, 2018, Organovo will issue its fiscal first-quarter 2019 earnings press release, which will be available at http://www.organovo.com.  To participate in the teleconference, callers can dial the following numbers:

Fraser Institute Media Advisory: Does lowering the price for pharmaceuticals affect the availability of medicine? New study coming Friday, July 20

VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- On Friday, July 20, the Fraser Institute will release a new study on Canadian health-care policy.

Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts

PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A10 in the non-small cell lung cancer (NSCLC) study. Based on these data, the Safety Review Committee (SRC) has endorsed dose escalation to the third dose cohorts in both MAGE-A10 pilot studies (i.e., the NSCLC and the triple tumor studies).

Myriad Announces Coverage Decision by Kroger® Prescription Plans for Vectra DA®

SALT LAKE CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide  Vectra® DA as a benefit option for Kroger Prescription Plan employer group clients.   

Magnesium Phosphate Market to hit $1.5bn by 2024: Global Market Insights, Inc.

Magnesium Phosphate Market Regional Analysis covering 20+ Countries and 18 Company Profiles (Jost Chemical, American Elements, Anmol Chemicals Group, Celtic Chemicals, Hap Seng, Hindustan Phosphate, Innophos Holdings, Manus Aktteva Biopharma, The Mosaic Company, Nikunj Chemicals, Nithyasri Chemicals, Nexgen Chemicals, Powder Pack Chem, Pacific Chemicals Company, Refractory Minerals Company, Redox, Shanpar, Triveni Chemicals) & Forecasts to 2024

SOHM, Inc. Reports $180,000 of Total Revenue and a Gross Profit of $95,292 for the First Qtr of 2018

Chino Hills, CA, July 17, 2018 (GLOBE NEWSWIRE) -- SOHM, Inc. (PINKSHEETS: SHMN) a globally-known generic pharmaceutical manufacturer, release its first Qtr of 2018. 

Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops

Research to Explore Potential for CAP-2003 to Address Trauma-related Injuries

CytoDyn to Present at Singular Summer Solstice 2018 Conference on July 19

VANCOUVER, Washington, July 16, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, announces that Nader Pourhassan, Ph.D., President and CEO, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19, at 2:50 p.m. Eastern time (11:50 a.m. Pacific time).  The conference is being held at the Convene Conference Center in New York City.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2018 Financial Results

OLDSMAR, Fla., July 16, 2018 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2018. 

Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients

SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nohla’s lead product candidate, dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). Dilanubicel received Orphan Drug Designation from the European Commission in January 2018.

Diamond Equity Research Initiates Coverage on AquaBounty Technologies Inc. (NASDAQ: AQB) with a Valuation of $4.25 Per Share

NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of AquaBounty Technologies Inc. (NASDAQ:AQB). The in-depth 25-page initiation report includes detailed information on the AquaBounty business model, services, industry, valuation, management and risks.

CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

Approximately 81% of patients completing PRO 140 trial demonstrated suppressed viral load with plasma HIV-1 RNA viral load of less than 50 copies/mL and 92% had viral load of less than 400 cp/mL

Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration

 

Sunnyvale, July 16, 2018 (GLOBE NEWSWIRE) -- July 16, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH).  The instrumentation reads and reports test results for the company’s allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson’s Disease (PD).

Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program

Company Release no. 13/2018